The correlation between the expression of FLT3 and the presence of a greater number of immune cells, such as CD4+ T, CD8+ T, myeloid dendritic cells, and neutrophils in the tumor tissue and the association with a reduced burden of tumor mutations suggests the rationale for the positive predictive significance of FLT3 in tumor prognosis and for a possible use of FLT3L as immunotherapy [4]. This evidence concerns the gene CD4 and neoplasm.